GB Sciences, Inc.
3550 W Teco Avenue
About GB Sciences, Inc.GB Sciences is science-informed and patient-inspired. Here we create medicines, therapies and treatments for a variety of ailments with the extracted compounds of the cannabis plant.
CEO: John Poss
CSO: Andrea Small-Howard
CFO: Ksenia Griswold
FOLLOW GB SCIENCES:
Tweets by GB Sciences
70 articles with GB Sciences, Inc.
GB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing Pharmaceuticals
GB Sciences, Inc. and Purisys, LLC, the global industry leader in ultra-high purity, pharmaceutical grade cannabinoid supply, announced that GB Sciences has selected Purisys as their preferred vendor for the active pharmaceutical ingredients used in formulating GB Sciences' proprietary, cannabinoid-containing, optimized therapeutic mixtures.
GBS newest proprietary drug discovery platform uses data analytics and machine learning to gain valuable predictive insights into the likely efficacy of novel plant-derived therapeutics. This unique ability allows researchers to reduce the time and money required for novel, plant-based combination drugs to get to market.
GB Sciences Files Provisional Patent Application for the Treatment of Chronic Inflammation Utilizing Its Novel Cannabinoid Containing Complex Mixtures (CCCM)
GB Sciences, Inc., has filed a provisional patent application, assigned to GBS Global Biopharma, Inc., for the use of its new proprietary cannabinoid containing complex mixtures for the treatment of chronic inflammation.
GB Sciences Files Provisional Patent Application for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome (ARDS), the Leading Cause of Hospitalization and Deaths,
GB Sciences, Inc. (OTCQB:GBLX) has filed a provisional patent application, assigned to GBS Global Biopharma (GBS), Inc., for the use of its new proprietary cannabinoid containing complex mixtures (CCCM™) for the treatment of Cytokine Storm Syndromes (CSS), including acute respiratory distress syndrome (ARDS) in COVID-19 patients
GB Sciences Announces Outstanding Results from Preclinical Study of Its Parkinson's Disease Formulations
In an animal model of the disease, GB Sciences' formulations were able to reduce Parkinson's disease-like behavioral symptoms 'back to baseline' with negligible side effects.
GB Sciences Announces the Sale of The Majority Interest in Nevada Cultivation Operations to Focus on Its First Two Cannabinoid-Based Medical Compounds for Parkinson's Disease and Neuropathic Pain
This transaction will significantly reduce the Company's operating expenses, generate near-term working capital, and provide ongoing cashflow to enable the Company to focus solely on its biopharmaceutical and wellness assets.
GB Sciences Closes the Sale of GB Sciences Louisiana Cannabis Business to Wellcana Plus and Retains the Benefit of IP Developed Under GB Sciences Louisiana's Master Research and Development Agreement
The Sale, Which Immediately Eliminates Substantial Cash Obligations and Operating Expenses, Is Collateralized by Wellcana Plus's Interest in GB Sciences Louisiana.
GB Sciences Welcomes Esteemed Patent and Intellectual Property Attorney, Mr. Edmond DeFrank, to Its Board of Directors
GB Sciences, Inc. is pleased to announce that on October 23rd Mr. Edmond DeFrank joined its Board of Directors, filling a vacant seat.
GB Sciences, Inc. (OTCQB: GBLX) is featured in the October 2019 edition of the Marijuana Business Magazine.
GB Sciences, Inc. (OTCQB: GBLX), on Friday, September 13, 2019, filed an 8k announcing the sale of its 50% ownership stake in GB Sciences Louisiana, LLC.
U.S. Drug Enforcement Agency to Expand Cannabis Research: GB Sciences Submitted One of Thirty-Three Applications to Become a DEA-Registered Cannabis Supplier to U.S. Marijuana Researchers
GB Sciences, Inc. announced that it has received notification from the U.S. Drug Enforcement Agency that prior to making any decisions on the pending applications, the DEA intends to distribute regulations that govern the program of growing marijuana for scientific research under DEA registration.
8/30/2019Biopharma companies strengthen their leadership and boards with these appointments.
GB Sciences, Inc. announced the appointment to GB Sciences' executive team of Darin Carpenter as the company's new Executive Vice President for Operations and General Manager, bringing his extensive and nationally-recognized experience streamlining production, improving product quality, and increasing profitability to GBS.
GB Sciences Files Novel Patent Application For Chronic Pain Treatments Based On Proprietary Cannabis-Derived Formulations
In the US, chronic pain represents an estimated health burden of between $560 and $650 billion dollars.
GB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis and Hemp-Derived Ingredients
Oral thin films provide a convenient and accurate delivery system with increased bioavailability of cannabis active ingredients for patients
GBS Global Biopharma and National Research Council of Canada Begin Preclinical Studies on Chronic-Neuropathic Pain Therapies
GBS Global Biopharma's proprietary neuropathic pain therapies are orally-delivered, time-released nanoparticles containing myrcene and other cannabinoid-based ingredients
GB Sciences Louisiana Receives All Approvals and Announces the Opening of the Full Tissue Propagation Cannabis Cultivation at LSU Agricultural Center
Increases production and ensures a continuous supply of therapeutic cannabis for Louisiana patients.
Today: GB Sciences' Use of Controlled Cultivation, Product Formulations and Research Will Be Presented by Dr. Dominick Monaco at Cannabis Conference 2019, As Featured on Cover of Cannabis Business Times
GB Sciences, Inc. announced that Dr. Dominick Monaco, GB Sciences' Director of Medical Formulations, will be a featured speaker at the Las Vegas Cannabis Conference, April 2, at 4:40pm.
What consumers see is not what they get: Study finds almost no chemical diversity in Nevada's cannabis varieties
In Case You Missed It: GB Sciences Approved For Full Operations In Main LSU AgCenter Production Facility
With over five times the production capacity, main facility will allow for a perpetual harvest cycle, ensuring a continuous supply of therapeutic cannabis for patients throughout Louisiana.